AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10453931
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g oral ganciclovir daily for 8 weeks
Trial: 7605354
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day with APOE*2 allele
Trial: 7605354
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day with APOE*3 allele
Trial: 7605354
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/day with APOE*4 allele
Trial: 26752621
Drug: LY544344 (mGluR2/3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY544344 (mGluR2/3 agonist)
Trial: 25185277
Drug: Nasal steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal steroid spray (group A)
Trial: 25185277
Drug: Nasal irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal irrigation combined with nasal steroid (group C)
Trial: 19814624
Drug: 23-valent polysaccharide
RxNorm normalized name: pneumococcal 23-valent polysaccharide vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent polysaccharide vaccine (PPV)
Trial: 19916994
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of enoxaparin
Trial: 19916994
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of enoxaparin
Trial: 19242074
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% Diltiazem ointment
Trial: 16356429
Drug: Overtreatment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overtreatment of thyroid hormone replacement
Trial: 16356429
Drug: Suboptimal initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Suboptimal initial treatment of thyroid hormone replacement
Trial: 16356429
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment factors (free thyroxine and TSH concentrations)
Trial: 11977339
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) 378 mg/day
Trial: 11977339
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiagabine (TGB) 43 mg/g
Trial: 9231868
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment for chronic low back pain
Trial: 3301444
Drug: Optimized conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized conventional insulin therapy
Trial: 27789674
Drug: Neonatal vitamin
RxNorm normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who received a mega-dose of vitamin A postpartum
Trial: 27789674
Drug: Neonatal vitamin
RxNorm normalized name: NEONATAL VITAMIN Tablet
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal vitamin A supplementation (50,000 IU) among infants born to women who did not receive a mega-dose of vitamin A postpartum
Trial: 25394474
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy applied to the posterior two‐thirds of the dorsum of the tongue
Trial: 25394474
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (tongue scraper and photodynamic therapy)
Trial: 20153460
Drug: Residential Interpersonal
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 200 mg in 1 mL TOPICAL LIQUID [PRESIDENTIAL LEATHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential Interpersonal Treatment (RIPT)
Trial: 20153460
Drug: Residential Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential Cognitive Treatment (RCT)
Trial: 15909190
Drug: Saline infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusions (Control)
Trial: 12011543
Drug: Oral telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telithromycin 800 mg once daily for 5 days (followed by placebo for 5 days), n = 170
Trial: 12011543
Drug: Oral telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telithromycin 800 mg once daily for 10 days, n = 171
Trial: 12011543
Drug: Oral telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telithromycin 800 mg once daily for 5 days
Trial: 12011543
Drug: Oral telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral telithromycin 800 mg once daily for 10 days
Trial: 9614594
Drug: Doxepin (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (average daily dose: 169.4 ± 41.6 mg)
Trial: 9614594
Drug: Fluoxetine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (average daily dose: 36.8 ± 18 mg)
Trial: 8593195
Drug: Topical formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulations (including a new stabilized stannous fluoride dentifrice)
Trial: 2508382
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (2,000 kcal/12.4 g N)
Trial: 2508382
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (1,940 kcal/12.4 g N)
Trial: 22013492
Drug: Triple-target treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-target treatment (3T)
Trial: 17183987
Drug: Heparin (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (unfractionated or low-molecular weight)
Trial: 12657165
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetaminophen, given 6 times daily during 5 days
Trial: 12657165
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen, given 6 times daily during 5 days
Trial: 12657165
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given 6 times daily during 5 days
Trial: 9496390
Drug: Pamidronate 120
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 120 mg
Trial: 9064108
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg and 120 mg
Trial: 1722512
Drug: Parenteral gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral gold therapy combined with 120 mg intramuscular methylprednisolone acetate at Weeks 0, 4 and 8
Trial: 6357930
Drug: Diltiazem 60
RxNorm normalized name: DILTIAZEM 60MG 12HR CAP,SA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 60 mg three times daily
Trial: 6357930
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg four times daily
Trial: 27639387
Drug: Acotiamide 100
RxNorm normalized name: acetiamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acotiamide 100 mg × 3/day for 2 weeks
Trial: 27107325
Drug: Mid-luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-luteal phase surgical oophorectomy + oral tamoxifen
Trial: 27107325
Drug: Mid-follicular phase
RxNorm normalized name: Follicular hormone
DrugBank: Estrone (DB00655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mid-follicular phase surgical oophorectomy + oral tamoxifen
Trial: 27107325
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase surgery patients with progesterone levels <2 ng/ml
Trial: 27107325
Drug: Luteal phase
RxNorm normalized name: Nuphar lutea leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteal phase surgery patients with progesterone levels ≥2 ng/ml
Trial: 21733056
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate 1000 mg QD
Trial: 21733056
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate 1000 mg BID
Trial: 15774786
Drug: RT-first (radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT-first (radiation therapy before chemotherapy)
Trial: 31680023
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy (MBT) for PNES, 12 sessions
Trial: 24104532
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 15 mg 0.5% hyperbaric bupivacaine intrathecally
Trial: 24104532
Drug: Iliohypogastric ilioinguinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iliohypogastric ilioinguinal nerve block (IHNB) with 20 mL 0.5% plain bupivacaine
Trial: 11384804
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg daily for 6 months)
Trial: 8357888
Drug: Medication use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication use (including prescription and nonprescription)
Trial: 8357888
Drug: Multiple medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple medication use
Trial: 8357888
Drug: Nonprescription medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonprescription medication use
Trial: 8357888
Drug: Knowledge and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge and compliance with medication
Trial: 8357888
Drug: Multiple medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple medication use and wellbeing
Trial: 31801597
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy maintained before surgery
Trial: 31801597
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy interrupted and substituted with subcutaneous heparin
Trial: 28932091
Drug: Fixed-time split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-time split dose regimen
Trial: 28932091
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose regimen
Trial: 21272401
Drug: Ground hazelnuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground hazelnuts (30 g/d)
Trial: 21272401
Drug: Sliced hazelnuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliced hazelnuts (30 g/d)
Trial: 21272401
Drug: Whole hazelnuts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole hazelnuts (30 g/d)
Trial: 15636254
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of iodine (3-4 times a day as eye drops)
Trial: 9142433
Drug: Pimobendan 2.5
RxNorm normalized name: pimobendan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 2.5 mg single oral dose
Trial: 9142433
Drug: Pimobendan 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 5.0 mg single oral dose
Trial: 9142433
Drug: Pimobendan 2.5
RxNorm normalized name: pimobendan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 2.5 mg b.i.d. for 8 weeks
Trial: 9142433
Drug: Pimobendan 1.25
RxNorm normalized name: pimobendan 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimobendan 1.25 mg and 2.5 mg b.i.d. long-term treatment
Trial: 27806235
Drug: BIA 10‐2474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 10‐2474 (50 mg per day)
Trial: 24496169
Drug: Combined lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 μg/mL
Trial: 17417075
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halofantrine (HF) 500 mg alone
Trial: 17417075
Drug: Halofantrine (HF)
DrugBank: Halofantrine (DB01218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halofantrine (HF) 500 mg with prior administration of amodiaquine (AQ) 600 mg
Trial: 16311142
Drug: Olanzapine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (20 mg/day)
Trial: 12730556
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg/d
Trial: 2025853
Drug: 4250 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4250 cGy in 25 daily fractions for 5 weeks (Group 1)
Trial: 2025853
Drug: 4500 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4500 cGy in 25 daily fractions for 5 weeks (Group 2)
Trial: 2025853
Drug: 5100 cGy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5100 cGy in 30 daily fractions for 6 weeks (Group 3)
Trial: 2025853
Drug: Tumor grade,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor grade, pathologic stage, whole‐pelvis radiation dose, and the use of brachytherapy
Trial: 30958353
Drug: D-Cycloserine (DCS)
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-Cycloserine (DCS) 15 mg BID
Trial: 26683109
Drug: TRV130 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 2 mg q3h
Trial: 26683109
Drug: TRV130 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 3 mg q3h
Trial: 26683109
Drug: Morphine 4
RxNorm normalized name: morphine 4 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 4 mg q4h
Trial: 26683109
Drug: TRV130 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 2 mg
Trial: 26683109
Drug: TRV130 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 3 mg
Trial: 22395582
Drug: CT gel
RxNorm normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT gel (clindamycin phosphate 1.2% and tretinoin 0.025%)
Trial: 22395582
Drug: CT gel
RxNorm normalized name: PROSOURCE GELATEIN PLUS LIME W/MCT GEL,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT gel
Trial: 9585312
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 45 s (Group 1)
Trial: 9585312
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg followed by thiopental 4-6 mg/kg; intubation after 60 s (Group 2)
Trial: 9585312
Drug: Vecuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.01 mg/kg followed by thiopental and succinylcholine 1.5 mg/kg; intubation after 60 s (Group 3)
Trial: 72192
Drug: Oral non-absorbed
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral non-absorbed antibiotics
Trial: 23866300
Drug: Ziprasidone 20‐160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 20‐160 mg/day
Trial: 23866300
Drug: Olanzapine 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 5‐20 mg/day
Trial: 15116057
Drug: Docetaxel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (10 mg/m²) with ketoconazole (200 mg once daily for 3 days)
Trial: 9453428
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (1 g per day orally)
Trial: 2183879
Drug: Diazepam 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.20 mg/kg
Trial: 30629285
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide 10 mg
Trial: 18950300
Drug: Insulin-treated diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-treated diabetic patients
Trial: 9207639
Drug: Non-insulin-treated diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin-treated diabetic patients
Trial: 15136070
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg daily
Trial: 11230834
Drug: Eptifibatide with
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide with heparin
Trial: 11230834
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with heparin
Trial: 11230834
Drug: Eptifibatide without
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide without heparin
Trial: 11230834
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without heparin
Trial: 8963818
Drug: 5.00- to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.00- to 6.00-mm multizone treatment
Trial: 6608581
Drug: Moxalactam (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (200 mg/kg/day)
Trial: 6608581
Drug: Ampicillin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (400 mg/kg/day) plus chloramphenicol (75 mg/kg/day)
Trial: 26307133
Drug: CPS therapy
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPS therapy (Carboplatin, Paclitaxel, and Sorafenib)
Trial: 26307133
Drug: CP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP therapy (Carboplatin and Paclitaxel)
Trial: 22178164
Drug: Transvaginal ultrasound-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal ultrasound-guided embryo aspiration plus local administration of low-dose methotrexate (MTX)
Trial: 22178164
Drug: Systemic administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic administration of MTX plus curettage with hysteroscopy (control group)
Trial: 21146010
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of antibiotics during CVAP placement
Trial: 21146010
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics during CVAP placement
Trial: 17096683
Drug: Quinidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (4 mg kg(‐1) infusion for 20 min)
Trial: 10533479
Drug: Third intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third intensification block of chemotherapy (including dexamethasone)
Trial: 10533479
Drug: Continuing chemotherapy
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing chemotherapy
Trial: 7762325
Drug: Repeat FNA
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat FNA (with or without suppressive therapy)
Trial: 28795387
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg/day orally)
Trial: 31553438
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 intravenously) plus Docetaxel (60 mg/m2 i.v.)
Trial: 22128294
Drug: Misoprostol (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800 µg vaginally) after 200 mg mifepristone
Trial: 17576325
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg ketoconazole
Trial: 17576325
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 300 mg fluconazole with 2 weeks interval
Trial: 15168391
Drug: MMF (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (1,000 mg) + Ferrous sulfate (105 mg) coadministered
Trial: 15168391
Drug: MMF (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (1,000 mg) + Ferrous sulfate (4 hours later)
Trial: 15168391
Drug: MMF (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF (1,000 mg) alone (control)
Trial: 11452246
Drug: Morphine 0.4
RxNorm normalized name: morphine 0.4 mg/mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.4 mg, 1.2 mg, and 3.6 mg administered intraligamentarily
Trial: 11452246
Drug: Morphine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1.2 mg administered subcutaneously
Trial: 11452246
Drug: Morphine 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1.2 mg and Fentanyl 50 microg administered submucosally
Trial: 9570649
Drug: S. boulardii
RxNorm normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S. boulardii 113 g twice daily